|
| 38070147 | Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. | Neuro Oncol | 2024 |
| 37220314 | Impact of Prior Authorization on Patient Access to Cancer Care. | | 2023 |
| 36367837 | Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. | Neuro Oncol | 2023 |
| 35948282 | A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. | Neuro Oncol | 2023 |
| 35941343 | Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. | Ann Surg Oncol | 2023 |
| 36074155 | Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36435610 | Multidisciplinary Management of Brain Metastasis from Breast Cancer. | Hematology/Oncology Clinics of North America | 2023 |
| 38011567 | Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression. | Proc Natl Acad Sci U S A | 2023 |
| 38071708 | Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors. | | 2023 |
| 37693537 | Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy. | bioRxiv | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37210568 | Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. | Oncologist | 2023 |
| 37085569 | Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. | Nat Rev Clin Oncol | 2023 |
| 36583555 | Survival in male breast cancer over the past 3 decades. | J Natl Cancer Inst | 2023 |
| 36893691 | Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. | Cancer Treat Rev | 2023 |
| 37268724 | Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. | Nat Med | 2023 |
| 37268625 | Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. | NPJ Breast Cancer | 2023 |
| 37071254 | Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. | | 2023 |
| 37192427 | Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. | JCO Oncol Pract | 2023 |
| 36997605 | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. | NPJ Breast Cancer | 2023 |
| 37306554 | Keeping It in the Family: HER3 as a Target in Brain Metastases. | | 2023 |
| 36681001 | Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. | | 2023 |
| 36534524 | Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. | Clin Cancer Res | 2023 |
| 37356327 | Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. | Eur J Cancer | 2023 |
| 37227737 | Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases-Reply. | | 2023 |
| 37225714 | Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer. | | 2023 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35066788 | Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. | Breast Cancer Res Treat | 2022 |
| 35715538 | Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. | Breast Cancer Research and Treatment | 2022 |
| 35658506 | Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 35908120 | Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors. | Breast Cancer Res Treat | 2022 |
| 35841843 | Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. | Eur J Cancer | 2022 |
| 35766387 | The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. | J Clin Endocrinol Metab | 2022 |
| 36228333 | Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases. | ESMO Open | 2022 |
| 35762249 | Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. | Neuro Oncol | 2022 |
| 35641483 | STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. | Nat Commun | 2022 |
| 35640077 | Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 35640075 | Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 36210737 | Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer. | Cancer | 2022 |
| 36069365 | Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. | Cancer | 2022 |
| 35737367 | Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. | JAMA Oncol | 2022 |
| 35797509 | Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. | JCO Precis Oncol | 2022 |
| 35363308 | Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. | Clin Cancer Res | 2022 |
| 35475732 | Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science-Based Study. | JMIR Res Protoc | 2022 |
| 35923923 | Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. | Ther Adv Med Oncol | 2022 |
| 35671434 | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. | Am Soc Clin Oncol Educ Book | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 35290073 | Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. | Journal of Clinical Oncology | 2022 |
| 35024766 | Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. | JAMA Oncol | 2022 |
| 34953200 | Targeting brain metastases in breast cancer. | Cancer Treat Rev | 2022 |